The Latest Breaking News from Catalyst Pharmaceuticals

The IBD SmartSelect Composite Rating for Catalyst Pharmaceuticals increased from 94 to 98 Friday.

A Relative Strength Rating upgrade for Catalyst Pharmaceuticals shows improving technical performance.

Catalyst Pharmaceuticals doubled earnings expectations amid a strong launch for its new drug, Agamree. The biotech stock jumped Thursday.

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….

Catalyst Pharmaceuticals (CPRX) witnessed significant bottom-line growth in the first quarter but missed expectations. Does the biopharmaceutical company deserve a place in your portfolio in the near future? Let’s look at its financial metrics to get an idea….

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could…

The Nasdaq hit a 2023 high as Google soared on AI announcements. But the market rally showed weakness too.